(2E/Z)-2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]-2-propenamide | 846023-38-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2E/Z)-2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]-2-propenamide
• 英文别名: 2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]-prop-2-enamide；2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]prop-2-enamide；2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-(3-iodo-4-methoxyanilino)prop-2-enamide
• CAS: 846023-38-9
• 化学式: C₁₈H₁₄Cl₂IN₃O₃
• 分子量: 518.138
• InChiKey: AWCWIEJTUYSRQA-UHFFFAOYSA-N

物化性质

• 熔点：
  289-290 °C
• 沸点：
  620.1±55.0 °C(Predicted)
• 密度：
  1.726±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  83.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2E/Z)-2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]-2-propenamide 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 copper(ll) sulfate pentahydrate 、 四丁基氟化铵 、 二异丙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 7.25h， 生成 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)quinoline-3-carbonitrile
  参考文献：
  名称：

  Design, Synthesis and Pharmacokinetic Evaluation of a Novel Series of Triazole-Based Src Kinase Inhibitors with Anti-proliferative Activity

  摘要：

  Src 已被公认为治疗癌症的重要靶点。研究人员合成了一系列新型三唑类 Src 抑制剂，并以博舒替尼为参比化合物，在体外评估了它们对人类肺癌 A549 细胞的抗增殖活性。化合物 6 和 8 还进行了药代动力学性能评估，结果表明这两种化合物的血浆浓度较低，半衰期较短。

  DOI：

  10.2174/157018011793663930
• 作为产物：
  描述：

  2,4-二氯-5-甲氧基苯胺 在 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 21.0h， 生成 (2E/Z)-2-cyano-N-(2,4-dichloro-5-methoxyphenyl)-3-[(3-iodo-4-methoxyphenyl)amino]-2-propenamide
  参考文献：
  名称：

  Design, Synthesis and Pharmacokinetic Evaluation of a Novel Series of Triazole-Based Src Kinase Inhibitors with Anti-proliferative Activity

  摘要：

  Src 已被公认为治疗癌症的重要靶点。研究人员合成了一系列新型三唑类 Src 抑制剂，并以博舒替尼为参比化合物，在体外评估了它们对人类肺癌 A549 细胞的抗增殖活性。化合物 6 和 8 还进行了药代动力学性能评估，结果表明这两种化合物的血浆浓度较低，半衰期较短。

  DOI：

  10.2174/157018011793663930

文献信息

• Process for preparation of 4-amino-3-quinolinecarbonitriles
  申请人：Sutherland Wiggins Karen

  公开号：US20050043537A1

  公开（公告）日：2005-02-24

  This invention discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile comprising combining an amine compound with a cyanoacetic acid and an acid catalyst to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline in an alcoholic solvent and a trialkylorthoformate to yield a 3-amino-2-cyanoacrylamide; combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride in acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 4-amino-3-quinolinecarbonitrile and also discloses a process for the preparation of a 7-amino-thieno[3,2-b]pyridine-6-carbonitrile comprising combining a disubstituted 3-amino thiophene with a cyanoacetamide and trialkylorthoformate in an alcoholic solvent to obtain a 3-amino-2-cyanoacrylamide; and combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride and acetonitrile, butyronitrile, toluene or xylene, optionally in the presence of a catalyst to yield a 7-amino-thieno[3,2-b]pyridine-6-carbonitrile and also discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile by combining an amine compound with a cyanoacetic acid and a peptide coupling reagent to obtain a suspension; filtering the suspension to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-substituted aniline, an alcoholic solvent, and triethylorthoformate to yield a 3-amino-2-cyanoacrylamide; and combining the 3-amino-2-cyanoacrylamide with phosphorus oxychloride to yield a 4-amino-3-quinolinecarbonitrile.

  这项发明揭示了一种制备4-氨基-3-喹啉碳腈的过程，包括将胺化合物与氰乙酸和酸催化剂结合以产生氰乙酰胺；将氰乙酰胺与醇溶剂和三烷基正甲酸酯中的一个或多个取代苯胺缩合以产生3-氨基-2-氰基丙烯酰胺；将3-氨基-2-氰基丙烯酰胺与氯化磷在乙腈、丁腈、甲苯或二甲苯中结合，可选地在催化剂存在的情况下以产生4-氨基-3-喹啉碳腈，并且还揭示了一种制备7-氨基噻吩[3,2-b]吡啶-6-碳腈的过程，包括将二取代的3-氨基噻吩与氰乙酰胺和三烷基正甲酸酯在醇溶剂中结合以获得3-氨基-2-氰基丙烯酰胺；将3-氨基-2-氰基丙烯酰胺与氯化磷和乙腈、丁腈、甲苯或二甲苯结合，可选地在催化剂存在的情况下以产生7-氨基噻吩[3,2-b]吡啶-6-碳腈，并且还揭示了一种通过将胺化合物与氰乙酸和肽偶联试剂结合以获得悬浮液；过滤悬浮液以产生氰乙酰胺；将氰乙酰胺与一个或多个取代苯胺、醇溶剂和三乙基正甲酸酯缩合以产生3-氨基-2-氰基丙烯酰胺；将3-氨基-2-氰基丙烯酰胺与氯化磷结合以产生4-氨基-3-喹啉碳腈的制备过程。
• 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
  申请人：Boschelli Harris Diane

  公开号：US20060116375A1

  公开（公告）日：2006-06-01

  Compounds of the formula: wherein: R is methyl or ethyl; R′ and R″ are independently alkyl of 1 to 3 carbon atoms, or R′ and R″, taken together with the nitrogen to which they are attached, can form a 5 or 6 membered saturated ring which may optionally contain an additional heteroatom selected from NR′″, O or S(O) n ; n is 0-2; and R′″ is hydrogen or alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof, and their use for inhibiting vascular permeability caused by disease, injury or other trauma.

  该化合物的化学式为：其中：R为甲基或乙基；R′和R″分别是1至3个碳原子的烷基，或者R′和R″与它们所连接的氮原子一起形成一个5或6个成员的饱和环，该环可以选择性地包含一个来自NR′″、O或S（O）n的额外杂原子；n为0-2；R′″为氢或1至3个碳原子的烷基，以及其药学上可接受的盐，并且它们可用于抑制由疾病、损伤或其他创伤引起的血管通透性。
• Synthesis and Src Kinase Inhibitory Activity of a Series of 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles
  作者：Diane H. Boschelli、Biqi Wu、Fei Ye、Yan Wang、Jennifer M. Golas、Judy Lucas、Frank Boschelli

  DOI：10.1021/jm061031t

  日期：2006.12.1

  Compound 1 (SKI-606, bosutinib), a 7-alkoxy-4-[(2,4-dichloro-5-methoxyphenyl)amino]-3-quinolinecarbonitrile, is a potent inhibitor of Src kinase activity. We previously reported that analogs of 1 with thiophene groups at C-7 retained the Src activity of the parent compound. The corresponding C-7 furan analogs were prepared and it was found that the 3,5-substituted furan analog had increased activity compared to that of the 2,5-substituted furan isomer. Addition of a methoxy group at C-6 decreased the Src inhibitory activity of the C-7 2,5-substituted furan analog but increased the activity of the C-7 3,5-substituted furan isomer. This compound, 10, was a more potent Src inhibitor than 1 in both enzymatic and cell-based assays. The kinase selectivity profile of 10 was similar to that of 1, with 10 also inhibiting the activity of Abl and Lck. When tested in a solid tumor xenograft model, 10 had comparable oral activity to that of 1.
• WO2006/47262
  申请人：——

  公开号：——

  公开（公告）日：——